Possible role of 3′(2′)-phosphoadenosine-5′-phosphate phosphatase in the etiology and therapy of bipolar disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 5, 2003, Pages 723-727

  Agam, Galila ^a   Shaltiel, Galit ^b  

^a MENTAL HEALTH CENTER   (Israel)

^b NONE

Author keywords

Bipolar disorder; Enzymatic activity; Frontal cortex; Lithium; mRNA levels; PAP phosphatase; Protein levels

Indexed keywords

3'(2') PHOSPHOADENOSINE 5' PHOSPHATE PHOSPHATASE; LITHIUM ION; PHOSPHATASE; RIBOSOME RNA; TRANSFER RNA; UNCLASSIFIED DRUG;

BEHAVIOR; BIOACCUMULATION; BIPOLAR DISORDER; BRAIN TISSUE; CADAVER; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; FRONTAL CORTEX; GENE EXPRESSION; HUMAN; NONHUMAN; PATHOGENESIS; SHORT SURVEY; TISSUE DISTRIBUTION; YEAST;

EID: 0041630998     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00125-8     Document Type: Short Survey

References (35)

1. Alexander J.R., Benjamin J., Lerer B., Baron M., Belmaker R.H. Frequency of positive family history in bipolar patients in a catchment-area population. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 19:1995;367-373.
2. Avissar S., Schreiber G., Danon A., Belmaker R.H. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature. 331:1988;440-442.
3. Bashkirov V.I., Scherthan H., Solinger J.A., Buerstedde J.M., Heyer W.D. A mouse cytoplasmic exoribonuclease (mXRN1p) with preference for G4 tetraplex substrates. J. Cell Biol. 136:1997;761-773.
4. Belmaker R.H., Lerer B., Klein E. A comparison of carbamazepine with lithium in excited psychoses. Emrich H.M., Okuma T., Muller A.S. Anticonvulsants in Affective Disorders. 1984;198-204 Elsevier.
5. Berridge M.J. Phosphoinositides and signal transductions. Rev. Clin. Basic Pharmacol. 5:1985;5S-13S.
6. Borsu L., Presse F., Nahon J.L. The AROM gene: spliced mRNAs encoding new DNA/RNA binding proteins are transcribed from the opposite strand of the melanin-concentrating hormone gene in mammals. J. Biol. Chem. 275:2000;40576-40587.
7. Bowden C.L. Valproate in mania. Manji H., Bowden C. Bipolar Medications: Mechanisms of Action. 2000;357-366 American Psychiatric Press, Washington, DC.
8. Bullock B.P., McNeil G.P., Dobner P.R. Synergistic induction of neurotensin gene transcription in PC12 cells parallels changes in AP-1 activity. Brain Res. Mol. Brain Res. 27:1994;232-242.
9. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., Manji H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72:1999;879-882.
10. Coughtrie M.W. Catecholamine sulfation in health and disease. Adv. Pharmacol. 42:1998;339-342.
11. Dichtl B., Stevens A., Tollervey D. Lithium toxicity in yeast is due to the inhibition of RNA processing enzymes. EMBO J. 16:1997;7184-7195.
12. Ebstein R.P., Hermoni M., Belmaker R.H. The effect of lithium on noradrenaline-induced cyclic AMP accumulation in rat brain: inhibition after chronic treatment and absence of supersensitivity. J. Pharmacol. Exp. Ther. 213:1980;161-167.
13. Feinstein D.L. Potentiation of astroglial nitric oxide synthase type-2 expression by lithium chloride. J. Neurochem. 71:1998;883-886.
14. Gershon E.S., Martinez M., Goldin L., Gelernter J., Silver J. Detection of marker associations with a dominant disease gene in genetically complex and heterogeneous diseases. Am. J. Hum. Genet. 45:1989;578-585.
15. Gilad G.M., Gilad V.H. Brain polyamine stress response: recurrence after repetitive stressor and inhibition by lithium. J. Neurochem. 67:1996;1992-1996.
16. Hallcher L.M., Sherman W.R. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem. 255:1980;10896-10901.
17. Jope R.S. Anti-bipolar therapy: mechanism of action of lithium. Mol. Psychiatry. 4:1999;117-128.
18. Jope R.S., Williams M.B. Lithium and brain signal transduction systems. Biochem. Pharmacol. 47:1994;429-441.
19. Klaassen C.D., Boles J.W. Sulfation and sulfotransferases 5: the importance of 3′-phosphoadenosine 5′-phosphosulfate (PAPS) in the regulation of sulfation. FASEB J. 11:1997;404-418.
20. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 93:1996;8455-8459.
21. Lenox R.H., Wang L. Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol. Psychiatry. 8:2003;135-144.
22. Lopez-Coronado J.M., Belles J.M., Lesage F., Serrano R., Rodriguez P.L. A novel mammalian lithium-sensitive enzyme with a dual enzymatic activity, 3′-phosphoadenosine 5′-phosphate phosphatase and inositol-polyphosphate 1-phosphatase. J. Biol. Chem. 274:1999;16034-16039.
23. Manji H.K., Lenox R.H. Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse. 16:1994;11-28.
24. Massot O., Rousselle J.C., Fillion M.P., Januel D., Plantefol M., Fillion G. 5-HT1B receptors: a novel target for lithium. Possible involvement in mood disorders. Neuropsychopharmacology. 21:1999;530-541.
25. Miller J.C., Mathe A.A. Basal and stimulated C-fos mRNA expression in the rat brain: effect of chronic dietary lithium. Neuropsychopharmacology. 16:1997;408-418.
26. Muhlrad D., Decker C.J., Parker R. Deadenylation of the unstable mRNA encoded by the yeast MFA2 gene leads to decapping followed by 5′→3′ digestion of the transcript. Genes Dev. 8:1994;855-866.
27. Nonaka S., Hough C.J., Chuang D.M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc. Natl. Acad. Sci. U. S. A. 95:1998;2642-2647.
28. Presse F., Cardona B., Borsu L., Nahon J.L. Lithium increases melanin-concentrating hormone mRNA stability and inhibits tyrosine hydroxylase gene expression in PC12 cells. Brain Res. Mol. Brain Res. 52:1997;270-283.
29. Rocha E., Rodnight R. Chronic administration of lithium chloride increases immunodetectable glial fibrillary acidic protein in the rat hippocampus. J. Neurochem. 63:1994;1582-1584.
30. Shaltiel G., Kozlovsky N., Belmaker R.H., Agam G. 3′(2′)-phosphoadenosine 5′-phosphate phosphatase is reduced in postmortem frontal cortex of bipolar patients. Bipolar Disord. 4:2002;302-306.
31. Spiegelberg B.D., Xiong J.P., Smith J.J., Gu R.F., York J.D. Cloning and characterization of a mammalian lithium-sensitive bisphosphate 3′-nucleotidase inhibited by inositol 1,4-bisphosphate. J. Biol. Chem. 274:1999;13619-13628.
32. Unlap M.T., Jope R.S. Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells. Neuropsychopharmacology. 17:1997;12-17.
33. Yenush L., Belles J.M., Lopez-Coronado J.M., Gil-Mascarell R., Serrano R., Rodriguez P.L. A novel target of lithium therapy. FEBS Lett. 467:2000;321-325.
34. Zachrisson O., Mathe A.A., Stenfors C., Lindefors N. Region-specific effects of chronic lithium administration on neuropeptide Y and somatostatin mRNA expression in the rat brain. Neurosci. Lett. 194:1995;89-92.
35. Zachrisson O., Mathe A.A., Lindefors N. Effects of chronic lithium and electroconvulsive stimuli on cholecystokinin mRNA expression in the rat brain. Brain Res. Mol. Brain Res. 43:1996;347-350.